Please use this identifier to cite or link to this item:
|Title: ||商業計畫書- 臨床試驗夥伴學苑|
Business Plan – ClinMate Acadamy
Clinical Research Associate (CRA)
Clinical Research Coordinate (CTC)
|Issue Date: ||2021-03-02 14:26:54 (UTC+8)|
|Abstract: ||Clinical trial is the process of a human test in the drug development stage. The process is both costly and time-consuming. Cultivating clinical trial-related talents is conducive to the job seekers’ preparation in advance. For business owners, talent training also means more money saving and speed up for training development.|
Having accumulated over 15 years of clinical trial related work, we observed that the rapid increase in demand for CRCs/CRAs in Taiwan is deeply felt. However, the quality of talents has shown retarded growth. The main reason is that our clinical trials are still under the development stage compared to European countries and the United States where the environment is mature and the general public’s clinical trials have been accepted and popularized. Hence, the cultivation of outstanding and competitive clinical trial professionals has substantive value in enhancing the overall standards.
Clinical trials in Taiwan have long undergone development, with a focus on Asian clinical trial markets and in the hope of keeping pace with international standards. Clinical trials are no longer mainstream only in European countries and the United States. How to ensure the sustainable development of Taiwan’s strengths and continue to foster clinical trial talents are our founding purposes.
|Reference: ||1. FDA website: https://www.fda.gov/patients/drug-development-process/step-3-clinical-research|
2. CTC website: https://www.ccttt.org.tw/mooc/index.php
3. CRA definition: https://en.wikipedia.org/wiki/Clinical_research_associate
4. CRC definition: https://en.wikipedia.org/wiki/Clinical_research_coordinator
6. Adam and Brantner (2006). Estimating the cost of drug development: Is it really 802 million dollars? Health Affairs (Millwood), 25(2), 420-428.
7. Kola and Landis (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews, 3, 711-715.
8. Rho, Jay P. and Louie, Stan G. Handbook of Pharmaceutical Biotechnology. (New York: Pharmaceutical Products Press, 2003).
9. Schacter, Bernice. Biotechnology and Your Health: Pharmaceutical Applications. (Philadelphia: Chelsea House Publishers, 2006).
10. Speid, Lorna. Clinical Trials: What Patients and Healthy Volunteers Need to Know. (Oxford: Oxford University Press, 2010).
11. Zanders, Edward D. The Science and Business of Drugs Discovery: Demystifying the Jargon. (New York: Springer, 2011).
13. Clinical trials in Asia: A World Health Organization database study. Sheraz Ali, Oluwaseun Egunsola, Zaheer Ud Din Babar, Syed Shahzad Hasan Perspect Clin Res. 2019 Jul-Sep; 10(3): 121–124
14. Moore T, Zhang H, Anderson G, Alexander GC. Estimated costs of pivotal trials for novel therapeutic agents approved the US Food and Drug Administration, 2015-2016 [published online September 24, 2018]. JAMA Intern Med.
|Source URI: ||http://thesis.lib.nccu.edu.tw/record/#G0102933016|
|Data Type: ||thesis|
|Appears in Collections:||[國際經營管理英語碩士學程IMBA] 學位論文|
Files in This Item:
There are no files associated with this item.
All items in 政大典藏 are protected by copyright, with all rights reserved.